Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab.

Steffen PfeufferTobias RuckRefik PulLeoni RolfesCatharina KorsukewitzMarc PawlitzkiBrigitte WildemannLuisa KlotzChristoph KleinschnitzAntonio ScalfariHeinz WiendlSven G Meuth

Published in: Journal of neurology, neurosurgery, and psychiatry (2021)

In the real-world setting, we demonstrated suboptimal disease control and increased risk of secondary autoimmunity following alemtuzumab, among patients previously treated with fingolimod. These data can provide guidance for improving MS therapeutic management.

Keyphrases

multiple sclerosis
mass spectrometry
electronic health record
big data
deep learning
smoking cessation